By Dean Seal

Inspire Medical Systems Inc. said the Food and Drug Administration has granted approval for the use of full-body magnetic resonance imaging scans in conjunction with its sleep apnea therapy.

The Golden Valley, Minn.-based company, which develops treatments for patients with obstructive sleep apnea, previously had approval to use MRI scans for only the head, neck and extremities.

The expansion to full-body capabilities is retroactive, meaning it will apply to all patients that already have the company's Inspire IV neurostimulator device in place.

"Providing the full range of scan options enables us to better help all current and future patients with their imaging needs," Chief Executive Tim Herbert said.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

July 06, 2022 08:42 ET (12:42 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Inspire Medical Systems (NYSE:INSP)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Inspire Medical Systems.
Inspire Medical Systems (NYSE:INSP)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Inspire Medical Systems.